Biography

Elizabeth Maher, M.D., Ph.D., is a Professor in the Department of Internal Medicine and the Department of Neurology and a member of the Division of Hematology and Oncology

There is a major therapeutic benefit in understanding what you’ve got, believing you will do well, and trusting the team that is treating you.

Originally from Nova Scotia, Canada, Dr. Maher holds a bachelor's degree in biology from Amherst College in Massachusetts, where she graduated cum laude. she completed her postdoctorate degree in physiology at Mcgill University in Montreal. She then earned her medical degree at McGill University. She completed internal medicine residency training at the University of Toronto.

Dr. Maher completed multiple fellowships during her career. She did fellowships in hematology and oncology and internal medicine at Harvard Medical School, a fellowship in the Hypertension Research Unit at the University of Medicine and Dentistry of New Jersey, a neurology fellowship at the Children's Hospital of Boston, a fellowship in physiology at McGill University, and a fellowship in adult oncology at the Dana-Farber Cancer Institute at Harvard Medical School.

Certified by the American Board of Internal Medicine in medical oncology, Dr. Maher joined the UT Southwestern faculty in 2006. She is now the Director of Translational Research for the Neuro-Oncology Program at UT Southwestern and the Director of the Crystal Ball Charity Center for Pediatric Brain and Neurological Diseases.

At UT Southwestern, Dr. Maher is a member of the Supporting Women Achieving Greatness (SWAG) Committee and the Charles Y.C. and Jane Pak Breast Cancer - Bon Initiative Advisory Committee.

Dr. Maher is a member of several professional societies, including the American Society of Clinical Oncology, the Society of Neuro-Oncology, and the American Association of Cancer Research.

Education

Other Post Graduate Training
McGill University Faculty of Medicine (1989)
Graduate School
McGill University Faculty of Medicine (1989), Physiology
Medical School
McGill University Faculty of Medicine (1993)
Internship/Residency
University of Toronto Hospitals, Canada (1996), Internal Medicine
Fellowship
Dana-Farber Cancer Institute (1999), Hematology Oncology

Research Interest

  • Development of improved imaging techniques for brain tumors
  • Primary and metastatic brain tumors
  • Role of altered metabolism in the progression of malignant gliomas.

Publications

Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial (Nature Medicine, (2023), 29, 3, (615-622), 10.1038/s41591-022-02141-2)
Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF Nature medicine 2024 Jan 30 302
Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment
Cai Q, Li X, Xiong H, Fan H, Gao X, Vemireddy V, Margolis R, Li J, Ge X, Giannotta M, Hoyt K, Maher E, Bachoo R, Qin Z Nature communications 2023 Dec 14
Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution
Zhang H, Yu X, Ye J, Li H, Hu J, Tan Y, Fang Y, Akbay E, Yu F, Weng C, Sankaran VG, Bachoo RM, Maher E, Minna J, Zhang A, Li B Cancer Cell 2023 Oct 41 1788-1802.e10
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF Nature medicine 2023 Mar 29 615-622
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff IK, Van Den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, De La Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF New England Journal of Medicine 2023 389 589-601
Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Dan TD, Patel TR, Vo D Discover Oncology 2022 Dec 13
Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients
Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Lee M, Dan TD, Patel TR, Vo D Frontiers in Oncology 2022 Sep 12
Primary central nervous system lymphoma: A real-world comparison of therapy access and outcomes by hospital setting
Patel AM, Ali O, Kainthla R, Rizvi SM, Awan FT, Patel T, Pan E, Maher E, Desai NB, Timmerman R, Kumar KA, Ramakrishnan Geethakumari P Neuro-Oncology Practice 2022 May 9 183-192
Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate
Ganji SK, An Z, Tiwari V, Chang Y, Patel TR, Maher EA, Choi C Magnetic resonance in medicine 2022 Mar 87 1150-1164
Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm
Askari P, Dimitrov IE, Ganji SK, Tiwari V, Levy M, Patel TR, Pan E, Mickey BE, Malloy CR, Maher EA, Choi C Magnetic resonance in medicine 2021 Oct 86 1818-1828

Professional Associations/Affiliations

  • American Society of Clinical Oncology (2001)
  • Society for Neuro-Oncology (2003)